Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Hematological Malignancies (3567
)
Non-Hodgkin’s Lymphoma (922
)
Hodgkin Lymphoma (59
)
Hematological Malignancies (3567
)
Non-Hodgkin’s Lymphoma (922
)
Hodgkin Lymphoma (59
)
›
Associations
(1064)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
epcoritamab
Sensitive: A1 - Approval
FDA - 1 week (New A1)
epcoritamab
Sensitive
:
A1
FDA - 1wk
epcoritamab
Sensitive: A1 - Approval
FDA - 1 week
epcoritamab
Sensitive
:
A1
FDA - 1 week - (New A1)
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
IMPT-314
Sensitive: B - Late Trials
PRNewswire - 1 week (New B)
IMPT-314
Sensitive
:
B
PRNewswire - 1wk
IMPT-314
Sensitive: B - Late Trials
PRNewswire - 1 week
IMPT-314
Sensitive
:
B
PRNewswire - 1 week - (New B)
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
IMPT-314
Sensitive: B - Late Trials
PRNewswire - 1 week (New B)
IMPT-314
Sensitive
:
B
PRNewswire - 1wk
IMPT-314
Sensitive: B - Late Trials
PRNewswire - 1 week
IMPT-314
Sensitive
:
B
PRNewswire - 1 week - (New B)
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + zanubrutinib
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
rituximab + zanubrutinib
Sensitive
:
A2
NCCN - 2wk
rituximab + zanubrutinib
Sensitive: A2 - Guideline
NCCN - 2 weeks
rituximab + zanubrutinib
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + acalabrutinib
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
rituximab + acalabrutinib
Sensitive
:
A2
NCCN - 2wk
rituximab + acalabrutinib
Sensitive: A2 - Guideline
NCCN - 2 weeks
rituximab + acalabrutinib
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
R-Maxi-CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
R-Maxi-CHOP
Sensitive
:
A2
NCCN - 2wk
R-Maxi-CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks
R-Maxi-CHOP
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
R-DHAP + R-CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
R-DHAP + R-CHOP
Sensitive
:
A2
NCCN - 2wk
R-DHAP + R-CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks
R-DHAP + R-CHOP
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
R-DHAX + R-CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
R-DHAX + R-CHOP
Sensitive
:
A2
NCCN - 2wk
R-DHAX + R-CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks
R-DHAX + R-CHOP
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
R-DHAC + R-CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks (New A2)
R-DHAC + R-CHOP
Sensitive
:
A2
NCCN - 2wk
R-DHAC + R-CHOP
Sensitive: A2 - Guideline
NCCN - 2 weeks
R-DHAC + R-CHOP
Sensitive
:
A2
NCCN - 2 weeks - (New A2)
MYD88 mutation
Waldenstrom Macroglobulinemia
MYD88 mutation
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
EHA 2023 - 2 weeks (New B)
zanubrutinib
Sensitive
:
B
EHA 2023 - 2wk
zanubrutinib
Sensitive: B - Late Trials
EHA 2023 - 2 weeks
zanubrutinib
Sensitive
:
B
EHA 2023 - 2 weeks - (New B)
PD-L1 expression
Diffuse Large B Cell Lymphoma
PD-L1 expression
Diffuse Large B Cell Lymphoma
pembrolizumab + MVP-S
Sensitive: C3 – Early Trials
Eur J Haematol - 2 weeks (New C3)
pembrolizumab + MVP-S
Sensitive
:
C3
Eur J Haematol - 2wk
pembrolizumab + MVP-S
Sensitive: C3 – Early Trials
Eur J Haematol - 2 weeks
pembrolizumab + MVP-S
Sensitive
:
C3
Eur J Haematol - 2 weeks - (New C3)
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
pembrolizumab + MVP-S
Sensitive: C3 – Early Trials
Eur J Haematol - 2 weeks (New C3)
pembrolizumab + MVP-S
Sensitive
:
C3
Eur J Haematol - 2wk
pembrolizumab + MVP-S
Sensitive: C3 – Early Trials
Eur J Haematol - 2 weeks
pembrolizumab + MVP-S
Sensitive
:
C3
Eur J Haematol - 2 weeks - (New C3)
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
acalabrutinib + KRT-232
Sensitive: C3 – Early Trials
EHA 2023 - 2 weeks (New C3)
acalabrutinib + KRT-232
Sensitive
:
C3
EHA 2023 - 2wk
acalabrutinib + KRT-232
Sensitive: C3 – Early Trials
EHA 2023 - 2 weeks
acalabrutinib + KRT-232
Sensitive
:
C3
EHA 2023 - 2 weeks - (New C3)
LMO2 overexpression
T Cell Non-Hodgkin Lymphoma
LMO2 overexpression
T Cell Non-Hodgkin Lymphoma
fluzoparib
Sensitive: C3 – Early Trials
EHA 2023 - 2 weeks (New C3)
fluzoparib
Sensitive
:
C3
EHA 2023 - 2wk
fluzoparib
Sensitive: C3 – Early Trials
EHA 2023 - 2 weeks
fluzoparib
Sensitive
:
C3
EHA 2023 - 2 weeks - (New C3)
LDH elevation
Non-Hodgkin’s Lymphoma
LDH elevation
Non-Hodgkin’s Lymphoma
ARI-0001
Resistant: C3 – Early Trials
EHA 2023 - 2 weeks (New C3)
ARI-0001
Resistant
:
C3
EHA 2023 - 2wk
ARI-0001
Resistant: C3 – Early Trials
EHA 2023 - 2 weeks
ARI-0001
Resistant
:
C3
EHA 2023 - 2 weeks - (New C3)
Chr del(17p)
Diffuse Large B Cell Lymphoma
Chr del(17p)
Diffuse Large B Cell Lymphoma
Immunotherapy
Resistant: C3 – Early Trials
EHA 2023 - 2 weeks (New C3)
Immunotherapy
Resistant
:
C3
EHA 2023 - 2wk
Immunotherapy
Resistant: C3 – Early Trials
EHA 2023 - 2 weeks
Immunotherapy
Resistant
:
C3
EHA 2023 - 2 weeks - (New C3)
TP53 deletion
Diffuse Large B Cell Lymphoma
TP53 deletion
Diffuse Large B Cell Lymphoma
Immunotherapy
Sensitive: C3 – Early Trials
EHA 2023 - 2 weeks (New C3)
Immunotherapy
Sensitive
:
C3
EHA 2023 - 2wk
Immunotherapy
Sensitive: C3 – Early Trials
EHA 2023 - 2 weeks
Immunotherapy
Sensitive
:
C3
EHA 2023 - 2 weeks - (New C3)
ALK positive
T Cell Non-Hodgkin Lymphoma
ALK positive
T Cell Non-Hodgkin Lymphoma
brigatinib
Sensitive: C3 – Early Trials
EHA 2023 - 2 weeks (New C3)
brigatinib
Sensitive
:
C3
EHA 2023 - 2wk
brigatinib
Sensitive: C3 – Early Trials
EHA 2023 - 2 weeks
brigatinib
Sensitive
:
C3
EHA 2023 - 2 weeks - (New C3)
ALK positive
Peripheral T-cell Lymphoma
ALK positive
Peripheral T-cell Lymphoma
crizotinib + LB-100
Sensitive: D – Preclinical
EHA 2023 - 2 weeks (New D)
crizotinib + LB-100
Sensitive
:
D
EHA 2023 - 2wk
crizotinib + LB-100
Sensitive: D – Preclinical
EHA 2023 - 2 weeks
crizotinib + LB-100
Sensitive
:
D
EHA 2023 - 2 weeks - (New D)
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 3 weeks (New A1)
lisocabtagene maraleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 3wk
lisocabtagene maraleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 3 weeks
lisocabtagene maraleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 3 weeks (New A1)
lisocabtagene maraleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 3wk
lisocabtagene maraleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 3 weeks
lisocabtagene maraleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 3 weeks (New A1)
lisocabtagene maraleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 3wk
lisocabtagene maraleucel
Sensitive: A1 - Approval
Bristol-Myers Squibb Press Release - 3 weeks
lisocabtagene maraleucel
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 3 weeks - (New A1)
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mediastinal B Cell Lymphoma
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
axicabtagene ciloleucel
Sensitive: A1 - Approval
axicabtagene ciloleucel
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
brexucabtagene autoleucel
Sensitive: A1 - Approval
brexucabtagene autoleucel
Sensitive
:
A1
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
ALK positive
Non-Hodgkin’s Lymphoma
ALK positive
Non-Hodgkin’s Lymphoma
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Lymphoma
No biomarker
Lymphoma
axicabtagene ciloleucel
Resistant: A1 - Approval
axicabtagene ciloleucel
Resistant
:
A1
axicabtagene ciloleucel
Resistant: A1 - Approval
axicabtagene ciloleucel
Resistant
:
A1
No biomarker
Diffuse Large B Cell Lymphoma
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
tisagenlecleucel-T
Sensitive: A1 - Approval
tisagenlecleucel-T
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
No biomarker
Burkitt Lymphoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
No biomarker
Burkitt Lymphoma
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
rituximab
Sensitive: A1 - Approval
rituximab
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
orelabrutinib
Sensitive: A1 - Approval
orelabrutinib
Sensitive
:
A1
TNFRSF8 positive
Hodgkin Lymphoma
TNFRSF8 positive
Hodgkin Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
lenalidomide
Sensitive: A1 - Approval
lenalidomide
Sensitive
:
A1
CD20 expression
Non-Hodgkin’s Lymphoma
CD20 expression
Non-Hodgkin’s Lymphoma
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
rituximab + lenalidomide
Sensitive: A1 - Approval
rituximab + lenalidomide
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
rituximab-abbs
Sensitive: A1 - Approval
rituximab-abbs
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
Rixathon (rituximab biosimilar)
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
obinutuzumab
Sensitive: A1 - Approval
obinutuzumab
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login